HMPL-689
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Marginal Zone Lymphoma
Conditions
Marginal Zone Lymphoma, Follicular Lymphoma
Trial Timeline
Apr 15, 2021 → Feb 29, 2024
NCT ID
NCT04849351About HMPL-689
HMPL-689 is a phase 2 stage product being developed by HUTCHMED for Marginal Zone Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04849351. Target conditions include Marginal Zone Lymphoma, Follicular Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04849351 | Phase 2 | Completed |
| NCT03786926 | Phase 1 | Terminated |
| NCT03128164 | Phase 1 | Completed |
Competing Products
10 competing products in Marginal Zone Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Copanlisib + Rituximab | Celltrion | Phase 2 | 52 |
| Rituximab + Pembrolizumab | Celltrion | Phase 2 | 52 |
| Pirtobrutinib + Rituximab | Eli Lilly | Phase 2 | 52 |
| Epcoritamab | AbbVie | Phase 2 | 52 |
| Rituximab + Venetoclax | AbbVie | Phase 2 | 52 |
| VAY736 + lenalidomide | Novartis | Phase 1 | 33 |
| PI3K inhibitor BKM120 + rituximab | Novartis | Phase 1 | 33 |
| Obinutuzumab | Roche | Phase 2 | 52 |
| Umbralisib | TG Therapeutics | Phase 2 | 49 |
| Loncastuximab tesirine 150 µg/Kg + Loncastuximab tesirine 75µg/Kg | ADC Therapeutics | Phase 2 | 44 |